DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 76 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactCompany

Dr Reddys Share Price Live Updates: Dr. Reddys Stock Details

Economic Times 2 hrs ago·30 Sept 2026, 3:16 am

Dr. Reddy's Laboratories is a major player in the global generic pharmaceuticals market, known for producing affordable medicines. The company has a significant presence in India and exports its products to over 125 countries. Investors often track the stock for its dividend yield and its performance in the volatile generic drug sector.

The stock's movement is closely watched by traders and long-term investors alike. Market participants analyze the company's quarterly results, particularly its revenue from key markets like the US and Europe. Any updates on regulatory approvals or new product launches can also influence the stock's performance in the short term.

What to watch next includes the company's upcoming earnings report and any announcements regarding its research and development pipeline. Investors should also keep an eye on broader market trends and sector-specific news that could impact the pharmaceutical industry as a whole.